# University College London

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/university-college-london
Canonical HTML page: https://gethealthbrief.com/entity/university-college-london

## Timeline

- **2028**: Commercial Scalability Assessment — Evaluation of bio-foundry partnerships to standardize the production of engineered scaffolds.
- **2027**: Regulatory Submission — Expected filing for Advanced Therapy Medicinal Product (ATMP) designation with the MHRA.
- **2026-Q4**: Expanded Clinical Trials — Anticipated start of Phase II trials involving a larger cohort of pediatric patients with long-gap OA.
- **2026-03-20**: Breakthrough Announcement — First successful lab-grown oesophagus for pediatric use is unveiled to the public.

## Recent coverage (2 stories)

### £10 aerogel toothpaste claims instant end to tooth sensitivity
2026-08-12 22:04:07 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A 10-year development effort by NHS maxillofacial surgeon Dr Niall Kent produced Ozen, an aerogel-based toothpaste that seals dentinal channels and releases remineralizing ions — the first new sensitivity patent in nearly three decades. Claims of instant relief are winning endorsement from high-profile sports dentistry but remain unverified by published clinical trials.
Full story: https://gethealthbrief.com/story/ozen-aerogel-toothpaste-instant-sensitivity-health

### First Lab-Grown Oesophagus Offers Hope for Children with Rare Conditions
2026-03-20 12:11:22 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

Researchers have successfully engineered the first lab-grown oesophagus, providing a transformative solution for children born with Oesophageal Atresia. This tissue-engineered breakthrough uses a patient's own cells to create a functional organ, potentially eliminating the need for high-risk invasive surgeries.
Full story: https://gethealthbrief.com/story/lab-grown-oesophagus-pediatric-breakthrough

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.